...Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) discontinued development of ezutromid (SMT C1100) after the candidate failed in the...
...Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K. Product: Ezutromid (SMT C1100...
...staining in imaged biopsies and safety Status: Development discontinued Milestone: NA Jennie Walters ezutromid (SMT C1100, bmn 195, VOX C1100, VOXC 1100) Ridinilazole...

...Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) discontinued development of ezutromid (SMT C1100) after the candidate failed in the...
...off $10.10 (80%) to $2.55 on NASDAQ. PhaseOut DMD enrolled 40 DMD patients ages 5-10. Ezutromid...
...to Summit's Utrophin Modulators" ). Sarepta slipped $6.26 to $129.27 Wednesday. Jennie Walters ezutromid (SMT C1100, bmn 195, VOX C1100, VOXC 1100) Sarepta...

...that twice-daily ezutromid (SMT C1100) reduced muscle damage in Duchenne muscular dystrophy patients. Compared to baseline, ezutromid...
...UTRN membrane staining in imaged biopsies and safety. Top-line 48-week data are expected in 3Q18. Ezutromid...
...Inc. (NASDAQ:SRPT), Cambridge, Mass. Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K. Product: Ezutromid (SMT C1100) (formerly BMN 195...

...reporting interim 24-week data from the Phase II PhaseOut DMD trial showing that twice-daily ezutromid (SMT C1100...
...Duchenne muscular dystrophy patients. Summit gained 37.50p (21%) to 215p in London. Compared to baseline, ezutromid...
...ages 5-10 and includes a long-term, extension phase. Top-line 48-week data are expected in 3Q18. Ezutromid...

...dystrophin. That’s a done deal,” Meier told BioCentury. As a small molecule modulator of utrophin, ezutromid...
...measuring utrophin levels as a secondary endpoint in the Phase II PhaseOut DMD trial of ezutromid...

...Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) completed enrollment in the Phase II PhaseOut DMD trial of ezutromid (SMT C1100...
...trial enrolled 40 ambulatory boys ages 5-10 with DMD to receive twice-daily 2.5 g oral ezutromid...
...Inc. (NASDAQ:SRPT), Cambridge, Mass. Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K. Product: Ezutromid (SMT C1100) (formerly BMN 195...

...Summit’s utrophin (UTRN) modulator pipeline to treat Duchenne muscular dystrophy (DMD). The deal includes Summit’s ezutromid...
...up to $482 million in development and regulatory milestones. The milestones comprise $192 million in ezutromid-related...
...the same rate as in the original territories. Sarepta said that all licensed compounds, excluding ezutromid...

...$5.70 (66%) to $14.35 on NASDAQ. The deal includes Summit's lead clinical candidate, ezutromid ( SMT C1100...
...eligible for $482 million in development and regulatory milestones. The milestones comprise $192 million in ezutromid-related...

...FDA granted rare pediatric disease designation to Summit’s ezutromid to treat Duchenne muscular dystrophy (DMD). The...
...June 27). Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K. Product: Ezutromid ( SMT C1100 ) (formerly BMN 195...

...Summit began the 48-week, open-label, international Phase II PhaseOut DMD trial to evaluate oral ezutromid in...
...patients ages 5-10. Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K. Product: Ezutromid (formerly SMT C1100 , BMN 195...